We are live on ! Find out more
IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Delisted

IMUC was delisted on the 16th of October, 2018.

17 hedge funds and large institutions have $1.04M invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

52% more capital invested

Capital invested by funds: $684K → $1.04M (+$355K)

6% more funds holding

Funds holding: 1617 (+1)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
4
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SM
1
Sabby Management
Florida
$445K -$52.8K -20,217 -13%
Renaissance Technologies
2
Renaissance Technologies
New York
$371K +$50.1K +19,200 +20%
Vanguard Group
3
Vanguard Group
Pennsylvania
$177K -$13.1K -5,034 -8%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$34K
IP
5
Intellectus Partners
California
$9K
BlackRock
6
BlackRock
New York
$2K +$1.75K +672 New
Morgan Stanley
7
Morgan Stanley
New York
$1K +$144 +55 +21%
UBS Group
8
UBS Group
Switzerland
-$3.1K -1,187 -90%
LTFS
9
Ladenburg Thalmann Financial Services
Florida
-$65 -25 -36%
IA
10
IFP Advisors
Florida
+$248 +95 New
Bank of America
11
Bank of America
North Carolina
+$337 +129 New